Lumic
Get app

Rekha Jhunjhunwala's Portfolio Shines in FY27

This "Insights" piece delves into the impressive performance of Rekha Jhunjhunwala's investment portfolio during FY27. Demonstrating the "power of compounding" and astute stock selection, her holdings comfortably surpassed the benchmark Sensex returns. The story highlights how solid "earnings" from companies like Titan played a pivotal role, adding significant value. Additionally, the steady contributions from private banks such as Federal Bank and Karur Vysya Bank underscore their consistent value creation in the Indian stock market. Lumic's analysis suggests that quality compounders continue to be market outperformers, offering valuable perspectives for investors navigating the dynamic Indian financial landscape.

Insights

Titan and Private Banks Drive Rekha Jhunjhunwala's Portfolio in FY27

about 2 hours ago · Lumic

Rekha Jhunjhunwala's investment portfolio performance in FY27, showcasing top stock holdings and market returns.
Lumic
about 2 hours ago
Titan and Private Banks Drive Rekha Jhunjhunwala's Portfolio in FY27
KEY POINTS
Rekhas' portfolio gained 20% in FY27, comfortably beating the Sensex's 7.7% return.
Titan added ₹3,469 crore in value, emerging as the portfolio's biggest contributor.
Federal Bank and Karur Vysya Bank strengthened returns with steady value creation.
LUMIC INSIGHT
Quality compounders continue to outperform the market
Business Standard·about 2 hours ago

More in Insights

Indian pharma stocks decline on US generic drug tariff plan, impacting the pharma sector's export outlook.
Lumic
22 minutes ago

Insights

Indian Pharma Stocks Fall on Trump's Generic Drug Tariff Plan

  • Nifty Pharma declined as Trump's proposed tariff plan weighed on export outlook.
  • Imported generic drugs stay duty-free for two years before phased US tariffs begin.
  • India's major drugmakers face long-term uncertainty in their largest export market.
LUMIC INSIGHT
US policy changes could reshape pharma export strategies.
Business Standard·22 minutes ago
SBI Mutual Fund IPO listing performance analysis, Grey Market Premium versus actual listing gains on Indian stock exchanges.
Lumic
about 4 hours ago

Insights

SBI Funds Debuts Strong, But GMP Hype Falls Short on Listing

  • Grey market premium of ₹104 indicated an 18% listing gain over the ₹574 issue price.
  • The ₹9,813 crore IPO was oversubscribed over 41 times, led by strong institutional demand.
  • Experts caution GMP is unofficial and actual listing depends on market sentiment.
LUMIC INSIGHT
GMP signals sentiment, not guaranteed listing gains.
Business Standard·about 4 hours ago